Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
SillaJen Inc banner
S

SillaJen Inc
KOSDAQ:215600

Watchlist Manager
SillaJen Inc
KOSDAQ:215600
Watchlist
Price: 3 625 KRW -3.72% Market Closed
Market Cap: ₩500.7B
Write Note Create Alert Ask AI

Gross Margin

47.3%
Current
Improving
by 15.7%
vs 3-y average of 31.6%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
47.3%
=
Gross Profit
₩3.7B
/
Revenue
₩7.8B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
47.3%
=
Gross Profit
₩3.7B
/
Revenue
₩7.8B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
SillaJen Inc
KOSDAQ:215600
500.4B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
409.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
198.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
193.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
72.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.1B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 83% of companies in Korea
Percentile
83rd
Based on 2 511 companies
83rd percentile
47.3%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

Other Profitability Ratios

SillaJen Inc
Glance View

Market Cap
500.7B KRW
Industry
Biotechnology

SillaJen, Inc. develops oncolytic immunotherapeutics virus. The company is headquartered in Seoul, Seoul. The company went IPO on 2016-12-06. The Company’s major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Intrinsic Value
1 179.34 KRW
Overvaluation 67%
Intrinsic Value
Price
S
What is Intrinsic Value?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
47.3%
=
Gross Profit
₩3.7B
/
Revenue
₩7.8B
What is SillaJen Inc's current Gross Margin?

The current Gross Margin for SillaJen Inc is 47.3%, which is above its 3-year median of 31.6%.

How has Gross Margin changed over time?

Over the last 3 years, SillaJen Inc’s Gross Margin has increased from 35.5% to 47.3%. During this period, it reached a low of 9.1% on Mar 31, 2025 and a high of 47.3% on Sep 30, 2025.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.